Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 May;118(2):181-91.
doi: 10.1016/j.pharmthera.2008.02.003. Epub 2008 Mar 2.

Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions

Affiliations
Review

Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions

Nicholas P Hays et al. Pharmacol Ther. 2008 May.

Abstract

Common complications of type 2 diabetes (T2D) are eye, kidney and nerve diseases, as well as an increased risk for the development of cardiovascular disease and cancer. The overwhelming influence of these conditions contributes to a decreased quality of life and life span, as well as significant economic consequences. Although obesity once served as a surrogate marker for the risk of T2D, we know now that excess adipose tissue secretes inflammatory cytokines that left unchecked, accelerate the progression to insulin resistance and T2D. In addition, excess alcohol consumption may also increase the risk of T2D. From a therapeutic standpoint, lifestyle interventions such as dietary modification and/or exercise training have been shown to improve glucose homeostasis but may not normalize the disease process unless weight loss is achieved and increased physical activity patterns are established. Furthermore, utilization of natural products may serve as a significant adjunct in the fight against insulin resistance but further research is needed to ascertain their validity. Since it is clear that pharmaceutical therapy plays a significant role in the treatment of insulin resistance, this review will also discuss some of the newly developed pharmaceutical therapies that may work in conjunction with lifestyle interventions, and lessen the burden of behavioral change as the only strategy against the development of T2D.

PubMed Disclaimer

References

    1. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. Journal of Clinical Investigation. 1995;96:88–98. - PMC - PubMed
    1. Althuis MD, Jordan NE, Ludington EA, Wittes JT. Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr. 2002;76:148–155. - PubMed
    1. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, Pillot B, Bado A, RTronche F, Mithieux G, Vaulont S, Burcelin R, Viollet B. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not by insulin. Endocrinology. 2006;147:2432–2441. - PubMed
    1. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabet Metab Res Rev. 2002;18:S5–S9. - PubMed
    1. Aronne L, Fujioka K, Aroda V, Chen K, Halseth AE, Kesty NC, Burns C, Lush CW, Weyer C. Progressive reduction in body weigh tfollowing treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007 May 15; Epub ahead of print. - PubMed

MeSH terms